GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases
Application
US20260098071A1
Kind: A1
Apr 09, 2026
Inventors
Tao Sun
Abstract
The present disclosure relates to a novel human glucagon-like peptide-1 (GLP-1) analog. Compared with the natural sequence of GLP-1, the GLP-1 analog has a remarkable effect in improving GLP-1-related diseases such as obesity, type 2 diabetes mellitus (T2DM), and fatty liver (FL), as well as mood disorders such as anxiety and depression.
CPC Classifications
C07K 14/575
A61P 3/04
A61P 3/10
A61P 25/22
A61P 25/24
A61K 38/00
Filing Date
2024-12-04
Application No.
18968327